Study of HCD122 in Adults With Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior Therapies

NCT00670592 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

111

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Hodgkin's Lymphoma
Hodgkin's Lymphoma

Interventions

DRUG: HCD122

Sponsor

Novartis Pharmaceuticals

Collaborators

[object Object]